Status:
COMPLETED
Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.
Lead Sponsor:
Catholic University of the Sacred Heart
Conditions:
Polycystic Ovary Syndrome
Estro-progestin Drugs
Eligibility:
FEMALE
18-35 years
Phase:
NA
Brief Summary
The estrogenic component of estro-progestin (EP) is responsible for a negative impact on the metabolic and lipid assessment in women with polycystic ovary syndrome (PCOS). The objective of this study...
Eligibility Criteria
Inclusion
- normal weight women with Polycystic ovary syndrome, diagnosed in accordance with Rotterdam Consensus Conference Criteria 2003.
Exclusion
- pregnancy
- past history of cardiovascular disease, diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 g oral glucose tolerance test), hypertension
- significant liver or renal impairment
- other hormonal dysfunction (hypothalamic, pituitary, thyroidal or adrenal causes for the clinical signs)
- neoplasms
- unstable mental illness
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01519401
Start Date
February 1 2010
End Date
July 1 2011
Last Update
July 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Catholic University of Sacred Heart
Rome, Italy, 00168